Compare PubMatic Inc (PUBM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? PubMatic Inc trades at $17.61 (market cap $860.90M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 8.7× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PUBM | SYRE | |
|---|---|---|
Market Cap | $860.90M | $7.52B |
Volume | 528,167 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $19.18 | $108.92 |
52-Week Low | $6.28 | $22.18 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $764.03M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $17.64, down 4.75% today but maintains strong technical momentum with bullish moving average signals. The company reported three consecutive quarterly EPS beats despite negative annual net income margins. Recent Q2 2026 results showed 10.5% revenue growth and a significant EPS beat of $0.12 versus $0.03 expected, driven by mobile app and CTV segment strength.
Wall Street maintains bullish sentiment with 11 buy ratings and a $19.89 consensus target, representing 13% upside. Key risks include CFO transition uncertainty and competitive ad-tech landscape pressure. The stock's premium valuation (P/E 132) requires continued execution on AI-driven growth initiatives to justify current levels.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
